Ruud Rubbers schreef op 18 september 2015 18:29:
[...]
Van die website en leuk om even over na te denken:
In other words, we've witnessed everything from bidding wars (see Allergan) that have pumped up proposed buyout valuations to just enormous premiums being offered, such as Merck's acquisition of clinical-stage hepatitis C drugmaker Idenix Pharmaceuticals for $3.85 billion, a nearly 240% premium to its prior-day closing value. With the understanding that Big Pharma and blue-chip biotech stocks were willing to pay quite the premium to acquire first-in-class, or complementary product portfolios and pipelines, small-, mid-, and even smaller large-cap biotech companies have maintained the upper hand. Now it appears that it could be Big Pharma and blue-chip biotech companies that reap the nasty side effects of this correction.
240% premie!